These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35179961)

  • 21. Expression of the adaptor protein Lnk in leukemia cells.
    Gery S; Gueller S; Nowak V; Sohn J; Hofmann WK; Koeffler HP
    Exp Hematol; 2009 May; 37(5):585-592.e2. PubMed ID: 19375649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
    Liberante FG; Pouryahya T; McMullin MF; Zhang SD; Mills KI
    Oncotarget; 2016 Feb; 7(6):6609-19. PubMed ID: 26735888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of recombinant human granulocyte colony stimulating factor and granulocyte-monocyte colony stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes.
    Nagler A; Ginzton N; Negrin R; Bang D; Donlon T; Greenberg P
    Leukemia; 1990 Mar; 4(3):193-202. PubMed ID: 1690318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.
    Fang J; Rhyasen G; Bolanos L; Rasch C; Varney M; Wunderlich M; Goyama S; Jansen G; Cloos J; Rigolino C; Cortelezzi A; Mulloy JC; Oliva EN; Cuzzola M; Starczynowski DT
    Blood; 2012 Jul; 120(4):858-67. PubMed ID: 22685174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells.
    Machado-Neto JA; de Melo Campos P; Favaro P; Lazarini M; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
    Leuk Res; 2014 Feb; 38(2):251-7. PubMed ID: 24355524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.
    Sperling AS; Gibson CJ; Ebert BL
    Nat Rev Cancer; 2017 Jan; 17(1):5-19. PubMed ID: 27834397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes.
    Yoshida A; Zokumasu K; Wano Y; Yamauchi T; Imamura S; Takagi K; Kishi S; Urasaki Y; Tohyama K; Ueda T
    Haematologica; 2012 Sep; 97(9):1372-9. PubMed ID: 22419576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
    Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
    Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia.
    Wetzler M; Kurzrock R; Estrov Z; Estey E; Talpaz M
    Leuk Res; 1995 Jan; 19(1):23-34. PubMed ID: 7837815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation.
    Ferrajoli A; Talpaz M; Kurzrock R; Harris D; Van Q; Estey EH; Estrov Z
    Leuk Lymphoma; 1998 Jul; 30(3-4):279-92. PubMed ID: 9713960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia.
    Martín-Izquierdo M; Abáigar M; Hernández-Sánchez JM; Tamborero D; López-Cadenas F; Ramos F; Lumbreras E; Madinaveitia-Ochoa A; Megido M; Labrador J; Sánchez-Real J; Olivier C; Dávila J; Aguilar C; Rodríguez JN; Martín-Nuñez G; Santos-Mínguez S; Miguel-García C; Benito R; Díez-Campelo M; Hernández-Rivas JM
    Haematologica; 2021 Aug; 106(8):2215-2223. PubMed ID: 32675227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes.
    Kalina U; Hofmann WK; Koschmieder S; Wagner S; Kauschat D; Hoelzer D; Ottmann OG
    Exp Hematol; 2000 Oct; 28(10):1158-63. PubMed ID: 11027834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
    Bacher U; Haferlach C; Alpermann T; Kern W; Schnittger S; Haferlach T
    Haematologica; 2011 Sep; 96(9):1284-92. PubMed ID: 21606170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. G-CSF for chromosome analysis of myeloid leukemias and MDS.
    Tsuchiya H; Higuchi S; Asou N; Yamaguchi K; Matsuda I; Yokoyama Y; Murakami T; Kaneko Y
    Cancer Genet Cytogenet; 1990 Jul; 47(2):277-9. PubMed ID: 1694102
    [No Abstract]   [Full Text] [Related]  

  • 35. SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis.
    Nian Q; Xiao Q; Wang L; Luo J; Chen LP; Yang ZS; Liu L
    Int J Mol Med; 2014 Apr; 33(4):856-62. PubMed ID: 24535175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and functional analysis of granulocyte colony-stimulating factor receptors on CD34++ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukaemia.
    Sultana TA; Harada H; Ito K; Tanaka H; Kyo T; Kimura A
    Br J Haematol; 2003 Apr; 121(1):63-75. PubMed ID: 12670333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ribosomal protein S14 silencing inhibits growth of acute myeloid leukemia transformed from myelodysplastic syndromes via activating p53.
    Wang L; Luo J; Nian Q; Xiao Q; Yang Z; Liu L
    Hematology; 2014 Jun; 19(4):225-31. PubMed ID: 24074450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of Yisui Jiedu Recipe on JAK2-STAT5 signal transduction pathway in bone marrow hematopoietic cells from patients with myelodysplastic syndrome-refractory anemia].
    Tian SL; Zhou YM; Huang T; Xue ZZ; He W
    Zhong Xi Yi Jie He Xue Bao; 2008 Feb; 6(2):185-9. PubMed ID: 18241656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What biologic factors predict for transformation to AML?
    Bejar R
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):341-345. PubMed ID: 30466744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.